Cingulate

Cingulate Graham Number

The Graham Number of Cingulate (CING) as of Oct 18, 2026 is 6.49 USD. In the previous year, Graham Number was 15.23 USD — a change of -57.39% (lower).

Graham Number

6.49USD

YoY

-57.39%

Last updated:

Graham Number of Cingulate is 2025 6.49 USD. Graham Number of Cingulate was 2024 15.23 USD. It decreases by -57.39% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc, headquartered in Kansas City, Kansas, is a US-based biopharmaceutical company operating in the Pharmaceuticals sector. The company focuses on developing and commercializing pharmaceutical products using its precision timed release (PTR) drug delivery platform, specifically targeting attention deficit/hyperactivity disorder (ADHD). Cingulate is developing two lead product candidates, CTx-1301 and CTx-1302, designed as single-tablet formulations with three release phases for children, adolescents, and adults with ADHD. The company, listed on October 7, 2021, employs 15 full-time staff. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Graham Number of Cingulate is 6.49 USD in 2025.

On Eulerpool you can find the complete historical development of Graham Number Cingulate since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Cingulate

All Key Metrics — Cingulate